Milestone Pharmaceuticals
Milestone Pharmaceuticals

Financials • Milestone Pharmaceuticals

MIST

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
15
-43
-12
L
L
113
L
-114
-
-41
0
5
-41
0
0
-
-
12/2022
5
-60
-12
L
L
66
L
-65
-
-62
-0
3
-62
0
0
-
-
12/2023
1
-61
-12
L
L
17
L
-16
-
-56
-0
48
-56
0
0
-
-
12/2024
0
-42
-12
0%
L
13
L
-16
-
-35
-0
32
-35
0
0
-
-
12/2025
2
-62
-12
L
L
42
L
-49
-
-57
-0
86
-57
0
0
-
-

To see all financials—including updated, you must be Premium.